<DOC>
	<DOCNO>NCT00191646</DOCNO>
	<brief_summary>This phase III randomize study compare induction treatment Gemcitabine Carboplatin versus Paclitaxel Carboplatin , without consolidation therapy patient evidence disease completion six cycle induction therapy . Patients disease induction therapy crossover receive single agent therapy .</brief_summary>
	<brief_title>An Ovarian , Primary Peritoneal Fallopian Tube Cancer Study Patients That Have Not Received Prior Chemotherapy</brief_title>
	<detailed_description>This study ( Study B9E-US-S302 ) multicenter , comparative , open-label randomize , superiority , trial evaluate Gemcitabine Carboplatin standard care . Both treatment arm give option receive elective consolidation therapy Paclitaxel 135 mg/m^2 give every 28 day one year . Patients achieve complete response crossover opposite single agent .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Key Patients histologic diagnosis primary peritoneal carcinoma , epithelial ovarian carcinoma fallopian tube carcinoma Stage IC , II , III IV . All patient must surgery fallopian , ovarian peritoneal carcinoma establish diagnosis tissue available histologic evaluation confirmation organ origin . Patients must enrol twelve week postoperatively . Patients must willing receive chemotherapy drug intravenously , intraperitoneal therapy part trial . Key Patients current diagnosis epithelial ovarian tumor low malignant potential ( Borderline carcinoma ) eligible . Patients receive prior radiotherapy portion abdominal cavity pelvis exclude Patients receive prior chemotherapy abdominal pelvic tumor exclude With exception nonmelanoma skin cancer specific malignancy patient ( ) evidence cancer present within last 5 year whose previous cancer treatment contraindicate protocol therapy exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>